Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Recent progress in small molecule agents for the targeted therapy of triple-negative breast cancer
Rajibul Islam, Kok Wai Lam
European Journal of Medicinal Chemistry (2020) Vol. 207, pp. 112812-112812
Closed Access | Times Cited: 37

Showing 1-25 of 37 citing articles:

Genesis and Mechanism of Some Cancer Types and an Overview on the Role of Diet and Nutrition in Cancer Prevention
Nurkhalida Kamal, Muna Ilowefah, Ayah Rebhi Hilles, et al.
Molecules (2022) Vol. 27, Iss. 6, pp. 1794-1794
Open Access | Times Cited: 49
Beyond cisplatin: New frontiers in metallodrugs for hard-to-treat triple negative breast cancer
Muhammad Nafees, Muhammad Hanif, Piaoping Yang
Coordination Chemistry Reviews (2023) Vol. 499, pp. 215507-215507
Closed Access | Times Cited: 23
Pyroptosis of Breast Cancer Stem Cells and Immune Activation Enabled by a Multifunctional Prodrug Photosensitizer
Yuqi Tang, Zhichao Wang, Quan Li
Advanced Functional Materials (2024) Vol. 34, Iss. 37
Closed Access | Times Cited: 10
Exploring the Potential of Metallodrugs as Chemotherapeutics for Triple Negative Breast Cancer
Nazia Nayeem, Marı́a Contel
Chemistry - A European Journal (2021) Vol. 27, Iss. 35, pp. 8891-8917
Open Access | Times Cited: 48
Crosslinked hydroxypropyl-β-cyclodextrin nanoparticles for improved efficacy of venetoclax against triple negative breast cancer
Sneha R. Chandani, Sayali Dighe, Oly Katari, et al.
International Journal of Pharmaceutics (2025), pp. 125296-125296
Closed Access
Precision Medicine and Triple-Negative Breast Cancer: Current Landscape and Future Directions
Fokhrul Hossain, Samarpan Majumder, Justin David, et al.
Cancers (2021) Vol. 13, Iss. 15, pp. 3739-3739
Open Access | Times Cited: 36
A multifunctional nanodiamond-based nanoplatform for the enhanced mild-temperature photothermal/chemo combination therapy of triple negative breast cancer via an autophagy regulation strategy
Xinyue Cui, Zhaoyuan Liang, Jianqing Lu, et al.
Nanoscale (2021) Vol. 13, Iss. 31, pp. 13375-13389
Closed Access | Times Cited: 34
Combination Therapy of Lox Inhibitor and Stimuli‐Responsive Drug for Mechanochemically Synergistic Breast Cancer Treatment
Shanshan Zhu, Tian Zhang, Huan Gao, et al.
Advanced Healthcare Materials (2023) Vol. 12, Iss. 21
Closed Access | Times Cited: 12
Synthesis of aspirin-curcumin mimic conjugates of potential antitumor and anti-SARS-CoV-2 properties
Aladdin M. Srour, Siva S. Panda, Ahmed Mostafa, et al.
Bioorganic Chemistry (2021) Vol. 117, pp. 105466-105466
Open Access | Times Cited: 27
Exosomes as a modulator of immune resistance in human cancers
Lanzhou Li, Chunyue Wang, Qiucheng Li, et al.
Cytokine & Growth Factor Reviews (2023) Vol. 73, pp. 135-149
Closed Access | Times Cited: 11
Synthesis and biological evaluation of novel ligustrazine-chalcone derivatives as potential anti-triple negative breast cancer agents
Yingqi Luo, Wenhao Wu, Dailong Zha, et al.
Bioorganic & Medicinal Chemistry Letters (2021) Vol. 47, pp. 128230-128230
Closed Access | Times Cited: 25
Discovery of β-carboline-(phenylsulfonyl)furoxan hybrids as potential anti-breast cancer agents
Xu Hu, Xiang Gao, Gang Gao, et al.
Bioorganic & Medicinal Chemistry Letters (2021) Vol. 40, pp. 127952-127952
Closed Access | Times Cited: 21
Insights into Mechanisms and Promising Triple Negative Breast Cancer Therapeutic Potential for a Water-Soluble Ruthenium Compound
Nazia Nayeem, Sami Sauma, Afruja Ahad, et al.
ACS Pharmacology & Translational Science (2024) Vol. 7, Iss. 5, pp. 1364-1376
Closed Access | Times Cited: 2
Enhanced drug delivery with nanocarriers: a comprehensive review of recent advances in breast cancer detection and treatment
Ruby Dhiman, Nancy Bazad, Riya Mukherjee, et al.
Discover Nano (2024) Vol. 19, Iss. 1
Open Access | Times Cited: 2
Intracellular Localization Studies of the Luminescent Analogue of an Anticancer Ruthenium Iminophosphorane with High Efficacy in a Triple-Negative Breast Cancer Mouse Model
Kirill Miachin, Virginia del Solar, Elsy El Khoury, et al.
Inorganic Chemistry (2021) Vol. 60, Iss. 24, pp. 19152-19164
Open Access | Times Cited: 18
Applications of lipid-engineered nanoplatforms in the delivery of various cancer therapeutics to surmount breast cancer
Ujala Gupta, Brojendra Nath Saren, Kedar Khaparkhuntikar, et al.
Journal of Controlled Release (2022) Vol. 348, pp. 1089-1115
Closed Access | Times Cited: 13
Bio-inspired Oxidative Stress Amplifier for Suppressing Cancer Metastasis and Imaging-Guided Combination Therapy
Geng Yang, Qingqing Su, Jiazhen Lv, et al.
ACS Applied Materials & Interfaces (2023) Vol. 15, Iss. 5, pp. 6572-6583
Closed Access | Times Cited: 6
Discovery of Novel Fedratinib-Based HDAC/JAK/BRD4 Triple Inhibitors with Remarkable Antitumor Activity against Triple Negative Breast Cancer
Chunlong Zhao, Yu Zhang, Jin’ge Zhang, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 20, pp. 14150-14174
Closed Access | Times Cited: 6
Conjugates Derived from Lapatinib Derivatives with Cancer Cell Stemness Inhibitors Effectively Reversed Drug Resistance in Triple-Negative Breast Cancer
Yuanjiang Wang, Zhaodan Lv, Feihong Chen, et al.
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 17, pp. 12877-12892
Closed Access | Times Cited: 15
Identification and optimization of 3-bromo-N’-(4-hydroxybenzylidene)-4-methylbenzohydrazide derivatives as mTOR inhibitors that induce autophagic cell death and apoptosis in triple-negative breast cancer
Tian Xu, Jifa Zhang, Chengcan Yang, et al.
European Journal of Medicinal Chemistry (2021) Vol. 219, pp. 113424-113424
Closed Access | Times Cited: 13
Targeted Cancer Therapy‐on‐A‐Chip
Heba Abed, R. Radha, Shabana Anjum, et al.
Advanced Healthcare Materials (2024) Vol. 13, Iss. 29
Open Access | Times Cited: 1
Synthesis of hybrids thiazole–quinoline, thiazole–indole and their analogs: in vitro anti-proliferative effects on cancer cell lines, DNA binding properties and molecular modeling
Paulo Fernando da Silva Santos-Júnior, Igor José dos Santos Nascimento, Edjan Carlos D. da Silva, et al.
New Journal of Chemistry (2021) Vol. 45, Iss. 31, pp. 13847-13859
Closed Access | Times Cited: 12
A bibliometric analysis of 16,826 triple-negative breast cancer publications using multiple machine learning algorithms: Progress in the past 17 years
Kangtao Wang, Chanjuan Zheng, Lian Xue, et al.
Frontiers in Medicine (2023) Vol. 10
Open Access | Times Cited: 4
Cadinane-type sesquiterpenoid dimeric diastereomers hibisceusones A-C from infected stems of Hibiscus tiliaceus with cytotoxic activity against triple-negative breast cancer cells
De-Li Chen, Guoxu Ma, Er-Lan Yang, et al.
Bioorganic Chemistry (2022) Vol. 127, pp. 105982-105982
Closed Access | Times Cited: 7
Synthesis and evaluation of novel thiosemicarbazone and semicarbazone analogs with both anti-proliferative and anti-metastatic activities against triple negative breast cancer
Chengfeng Bai, Shuangjie Wu, Shengnan Ren, et al.
Bioorganic & Medicinal Chemistry (2021) Vol. 37, pp. 116107-116107
Closed Access | Times Cited: 9
Page 1 - Next Page

Scroll to top